Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Promising advance in fight against African swine fever
African swine fever virus is a devastating and economically important disease of pigs.
Researchers identify novel proteins to test as vaccine candidates 

Scientists at The Pirbright Institute have made a promising advance in the quest for an African swine fever vaccine.

Writing in the Journal of Virology, researchers describe how they have identified a number of novel immunogenic proteins to test further as vaccine candidates.

“Such an advance is extremely timely due to the continuing spread of ASFV into Eastern Europe,” explained study leader Dr Linda Dixon. “Developing an effective and safe vaccine is therefore of increasing importance to prevent further spread.”

African swine fever virus (ASFV) is a devastating and economically important disease of pigs that is usually fatal. Prevalent in Russia, Sardinia, Sub-Saharan Africa and Eastern Europe, experts have warned that the disease is likely to spread further afield.

There is no vaccine available for ASFV which limits the available options for control. However, researchers at Pirbright have been working on a solution.

Until now, ASF vaccine development work has centred on live attenuated viruses. These are common viruses that have been genetically modified to prevent a full infection, but which can still trigger an immune response.

Although this method is common and effective, scientists say there may be safety issues since the vaccine may cause clinical signs and persist in animals. To overcome this problem, Dr Linda Dixon and her team set out to investigate proteins that induce immune responses that might offer the best protection against infection.

By inserting the gene code for these proteins into Vaccinia - a safe virus that is often used to deliver protective genes to a host - they were able to screen 30 per cent of ASFV genome and ranked 47 genes on their ability to produce proteins that would generate an immune response in pigs.

Researchers say the next step is to test the proteins that had the best immune response and incorporate them into safe vaccines that could eventually be used in the field.

 

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.